Targovax R&D Day: New York - October 11, 2018

New York, October 11, 2018

PLEASE JOIN US FOR A KOL EVENT

Leading experts discuss the oncolytic virus landscape and present interim data from Targovax’s ongoing melanoma and mesothelioma trials

 

 

General Agenda

11:30AM-12:00PM
Registration & Lunch

12:00-12:10PM
Welcome Remarks
Øystein Soug, CEO, Targovax

12:10-12:50PM
Oncolytic Virus Overview and Q&A
Dmitriy Zamarin, MD, PhD

12:50-1:30PM
Melanoma: the disease, CPIs, and lack of treatment options; Early ONCOS-102 data
Alexander N. Shoushtari, MD

1:30-1:50PM
Mesothelioma ORR Data
Magnus Jaderberg, CMO, Targovax

1:50-2:00PM
Closing Remarks
Øystein Soug, CEO, Targovax

RSVP for Event / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

Targovax [TRVX:OS] NKr333 MM MCap
On­co­lyt­ic ade­n­ovirus armed w im­mune sti­m­u­lat­ing trans­gene tar­get­ing bas­ket of I-O in­di­ca­tions. Strong re­sults from Part 1 (ON­COS-102/Keytru­da com­bo) trial in an­ti-PD1 re­frac­to­ry me­lano­ma: 33% ORR in 9 pts: 1 CR, 2 PRs; im­mune ac­ti­va­tion de­mon­s­trat­ed in all 9 pts. Jan 2020: exp ran­domized da­ta, Ph 1b/ 2 (me­sothe­lio­ma, n=31) w/che­mo [more in­for­ma­tion]

Location of the Event and Other Places